Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Engage
Data as at: 18/03/2024
In
Objective
To achieve a high level of capital growth by investing worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
AIC sector
Management group
Frostrow Capital
Company website
Launch date
28/04/1995
March
Domicile
United Kingdom
Fund manager
Sven H. Borho, Trevor M. Polischuk
Dividend frequency
Semi-Annually
Wind-up provisions
Continuation vote at every fifth AGM, the next of which will be in 2024.
Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
---|---|---|---|---|---|---|---|---|
1,792.90 | 2,047.74 | 326.50 | 372.91 | -12.45 | 1 | 0.95 | Jun, Nov | 0.8 (31/03/2023) |
Scroll
Dividends
Dividends declared in last 12 months
Ex-Dividend date | Payment date | Dividend amount | Special dividend | Financial year |
---|---|---|---|---|
23/11/2023 | 11/01/2024 | 0.700 | No | 2024 |
08/06/2023 | 26/07/2023 | 2.400 | No | 2023 |
Scroll
Performance (%)
Return type | 1 year | 3 years | 5 years | 10 years | |
---|---|---|---|---|---|
Worldwide Healthcare Trust | Share price total return | 7.8 | -8.6 | 23.8 | 162.7 |
Biotechnology & Healthcare AIC sector | Share price total return | 3.7 | -22.2 | 2.7 | 111.4 |
Scroll
Share structure
Number of shares
549,126,618
52,538,582
Traded volumes (number of shares)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 1,103,424 | 24,092,117 | 341,261,308 | 1,356,359,508 |
Average | N/A | 1,155,530 | 1,345,540 | 1,075,010 |
Scroll
Traded values (m)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 3.60 | 78.96 | 1,067.62 | 4,445.57 |
Average | N/A | 3.79 | 4.21 | 3.52 |
Scroll
Trading details
Top holdings
Data as at : 30/11/2023
Investment | % of total assets |
---|---|
Novo Nordisk A/S Class B | 7.5 |
Eli Lilly and Co | 6.7 |
Boston Scientific Corp | 6.0 |
AstraZeneca PLC | 6.0 |
Intuitive Surgical Inc | 5.1 |
Biogen Inc | 4.0 |
Merck & Co Inc | 3.7 |
Biomarin Pharmaceutical Inc | 3.7 |
Daiichi Sankyo Co Ltd | 3.5 |
Eisai Co Ltd | 2.9 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.